2023亚太国家SGLT-2抑制剂的临床实践专家共识:解读与思考  

Interpretation and discussion of the 2023 expert consensus statement on practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries

作　　者：王硕朋 方立明[1] 谢圣芳[1] 韦玲[1] 刘超[2] Wang Shuopeng;Fang Liming;Xie Shengfang;Wei Ling;Liu Chao(Department of Nephrology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210028,China;Department of Endocrinology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210028,China)

机构地区：[1]南京中医药大学附属中西医结合医院肾科,南京210028 [2]南京中医药大学附属中西医结合医院内分泌科,南京210028

出　　处：《国际内分泌代谢杂志》2024年第4期279-283,共5页International Journal of Endocrinology and Metabolism

基　　金：江苏省卫生健康委员会重点资助项目(ZD2021042)。

摘　　要：钠-葡萄糖共转运蛋白-2(SGLT-2)抑制剂的心肾保护作用已被多项大规模、多中心临床试验证实。2023年4月,亚太肾脏病学会颁布了SGLT-2抑制剂的临床实践专家共识,结合亚太地区的文化与风俗,聚焦于SGLT-2抑制剂的应用指征、常见不良反应和注意事项。专家共识给出9条建议以增强临床医生应用SGLT-2的信心,更好地管理可能受益于SGLT-2抑制剂的患者。The cardio-renal protective effect of sodium-glucose contransporter-2(SGLT-2)inhibitors has been extensively studied and validated through numerous large-scale,multi-center clinical trials.The Asia Pacific Society of Nephrology updated and published an expert consensus statement in April 2023.It has considered the distinct culture and customs of Asian Pacific region and has focused on providing guidelines for clinicians including the indications,common adverse effects,and important considerations for the use of SGLT-2 inhibitors.The editorial board has proposed nine specific recommendations and two flow charts to increase clinicians′confidence in initiating SGLT-2 inhibitors and to enhance their ability to effectively manage patients who may benefit from this class of drugs.

关 键 词：钠-葡萄糖共转运蛋白-2 抑制剂 泌尿生殖系统感染 酮症酸中毒 

分 类 号：R692[医药卫生—泌尿科学]